Department of Organic Chemistry, University of Barcelona, Barcelona, Spain.
Future Med Chem. 2013 Sep;5(13):1509-23. doi: 10.4155/fmc.13.135.
Schizophrenia is a serious life-long disease that affects a significant part of the adult population. Although there is considerably effective medication for the positive symptoms of the disease, none are available for the associated cognitive deficits. These deficits are a core feature of schizophrenia, and they severely impair the functionality and social integration of patients. POP is a promising target for the treatment of the cognitive deficits of schizophrenia. Inhibitors of this peptidase show cognition-enhancing properties, act through a complex mechanism and have suitable pharmacological properties. Nevertheless, several studies must be carried out in order to improve the design and clinical evaluation of these substances. Permeability to the brain, appropriate animal models and suitable indications are the main issues that must be addressed. However, current information supports the potential of POP as an interesting drug target for the treatment of the cognitive deficits related to schizophrenia.
精神分裂症是一种严重的终身疾病，影响着相当一部分成年人口。尽管有相当有效的药物可以治疗该疾病的阳性症状，但对于相关的认知缺陷却没有有效的治疗方法。这些缺陷是精神分裂症的核心特征，严重损害了患者的功能和社会融合能力。POP 是治疗精神分裂症认知缺陷的一个很有前途的靶点。这种肽酶的抑制剂显示出增强认知的特性，通过复杂的机制发挥作用，具有合适的药理学特性。然而，为了提高这些物质的设计和临床评估，还必须进行多项研究。需要解决的主要问题包括：脑通透性、合适的动物模型和合适的适应证。然而，目前的信息支持 POP 作为一种有潜力的药物靶点，用于治疗与精神分裂症相关的认知缺陷。
